Literature DB >> 22511308

Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis.

Hyung-Yoon Yoon1, Seon-Kyu Kim, Young-Won Kim, Ho Won Kang, Sang-Cheol Lee, Keun Ho Ryu, Ho Sun Shon, Wun-Jae Kim, Yong-June Kim.   

Abstract

A total of 149 human prostate tissues obtained from our institute were assessed: 52 specimens of benign prostate hyperplasia (BPH) and 97 specimens of prostate cancer (PCa). The methylation status of the genes of Adenomatous polyposis coli (APC) and glutathione-S-transferase-P1 (GSTP1) was analyzed by quantitative pyrosequencing. A methylation score (M score) was calculated to capture the combined methylation level of both genes. The methylation level of each single gene and that of both genes combined was significantly higher in PCa specimens than in BPH (each p < 0.001). The value of APC methylation, GSTP1 methylation, and M score for predicting PCa was measured by the area under the receiver operating characteristic (ROC) curve and reached 0.954, 0.942, and 0.983, respectively. The sensitivity and specificity of the M score in discriminating between PCa and BPH reached 92.8% and 100.0%, respectively. The M score was positively associated with the serum prostate-specific antigen (PSA) level (p trend < 0.001). Our study demonstrates that the quantitative measurement of two methylation markers might drastically improve the ability to discriminate PCa from BPH.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22511308     DOI: 10.1177/1087057112444445

Source DB:  PubMed          Journal:  J Biomol Screen        ISSN: 1087-0571


  8 in total

1.  Heterogeneity of DNA methylation in multifocal prostate cancer.

Authors:  Inga Serenaite; Kristina Daniunaite; Feliksas Jankevicius; Arvydas Laurinavicius; Donatas Petroska; Juozas R Lazutka; Sonata Jarmalaite
Journal:  Virchows Arch       Date:  2014-11-05       Impact factor: 4.064

2.  Aberrant promoter methylation of the RASSF1A and APC genes in epithelial ovarian carcinoma development.

Authors:  Rahul Bhagat; Shilpa Chadaga; C S Premalata; G Ramesh; C Ramesh; V R Pallavi; Lakshmi Krishnamoorthy
Journal:  Cell Oncol (Dordr)       Date:  2012-10-10       Impact factor: 6.730

Review 3.  APC gene hypermethylation and prostate cancer: a systematic review and meta-analysis.

Authors:  Yang Chen; Jie Li; Xiaoxiang Yu; Shuai Li; Xuerong Zhang; Zengnan Mo; Yanling Hu
Journal:  Eur J Hum Genet       Date:  2013-01-09       Impact factor: 4.246

Review 4.  Prostate cancer: the need for biomarkers and new therapeutic targets.

Authors:  Juliana Felgueiras; Joana Vieira Silva; Margarida Fardilha
Journal:  J Zhejiang Univ Sci B       Date:  2014-01       Impact factor: 3.066

Review 5.  Risk stratification in prostate cancer screening.

Authors:  Monique J Roobol; Sigrid V Carlsson
Journal:  Nat Rev Urol       Date:  2012-12-18       Impact factor: 14.432

6.  Copy number variation of chromosome 5A and its association with Q gene expression, morphological aberrations, and agronomic performance of winter wheat cultivars.

Authors:  Sebastian Förster; Erika Schumann; Mario Baumann; W Eberhard Weber; Klaus Pillen
Journal:  Theor Appl Genet       Date:  2013-09-28       Impact factor: 5.699

7.  Olfactomedin 4 downregulation is associated with tumor initiation, growth and progression in human prostate cancer.

Authors:  Hongzhen Li; Christine Kim; Wenli Liu; Jianqiong Zhu; Kay Chin; Jaime Rodriguez-Canales; Griffin P Rodgers
Journal:  Int J Cancer       Date:  2019-07-09       Impact factor: 7.396

8.  PITX2 methylation: a novel and effective biomarker for monitoring biochemical recurrence risk of prostate cancer.

Authors:  Qi Jiang; Mixue Xie; Mengye He; Feifei Yan; Ming Chen; Suzhen Xu; Xiaochen Zhang; Peng Shen
Journal:  Medicine (Baltimore)       Date:  2019-01       Impact factor: 1.889

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.